136 related articles for article (PubMed ID: 34672117)
1. DNA-Directed Patterning for Versatile Validation and Characterization of a Lipid-Based Nanoparticle Model of SARS-CoV-2.
Kozminsky M; Carey TR; Sohn LL
Adv Sci (Weinh); 2021 Dec; 8(23):e2101166. PubMed ID: 34672117
[TBL] [Abstract][Full Text] [Related]
2. Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia.
Asarnow D; Wang B; Lee WH; Hu Y; Huang CW; Faust B; Ng PML; Ngoh EZX; Bohn M; Bulkley D; Pizzorno A; Ary B; Tan HC; Lee CY; Minhat RA; Terrier O; Soh MK; Teo FJ; Yeap YYC; Seah SGK; Chan CEZ; Connelly E; Young NJ; Maurer-Stroh S; Renia L; Hanson BJ; Rosa-Calatrava M; Manglik A; Cheng Y; Craik CS; Wang CI
Cell; 2021 Jun; 184(12):3192-3204.e16. PubMed ID: 33974910
[TBL] [Abstract][Full Text] [Related]
3. Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.
Brown EEF; Rezaei R; Jamieson TR; Dave J; Martin NT; Singaravelu R; Crupi MJF; Boulton S; Tucker S; Duong J; Poutou J; Pelin A; Yasavoli-Sharahi H; Taha Z; Arulanandam R; Surendran A; Ghahremani M; Austin B; Matar C; Diallo JS; Bell JC; Ilkow CS; Azad T
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668756
[TBL] [Abstract][Full Text] [Related]
4. Structures of SARS-CoV-2 B.1.351 neutralizing antibodies provide insights into cocktail design against concerning variants.
Du S; Liu P; Zhang Z; Xiao T; Yasimayi A; Huang W; Wang Y; Cao Y; Xie XS; Xiao J
Cell Res; 2021 Oct; 31(10):1130-1133. PubMed ID: 34433900
[No Abstract] [Full Text] [Related]
5. Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion.
Salleh MZ; Derrick JP; Deris ZZ
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299045
[TBL] [Abstract][Full Text] [Related]
6. Receptor binding, immune escape, and protein stability direct the natural selection of SARS-CoV-2 variants.
Upadhyay V; Lucas A; Panja S; Miyauchi R; Mallela KMG
J Biol Chem; 2021 Oct; 297(4):101208. PubMed ID: 34543625
[TBL] [Abstract][Full Text] [Related]
7. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
[TBL] [Abstract][Full Text] [Related]
8. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
[TBL] [Abstract][Full Text] [Related]
9. Rapid Detection and Inhibition of SARS-CoV-2-Spike Mutation-Mediated Microthrombosis.
Satta S; Lai A; Cavallero S; Williamson C; Chen J; Blázquez-Medela AM; Roustaei M; Dillon BJ; Ashammakhi N; Carlo DD; Li Z; Sun R; Hsiai TK
Adv Sci (Weinh); 2021 Dec; 8(23):e2103266. PubMed ID: 34687279
[TBL] [Abstract][Full Text] [Related]
10. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Variants, RBD Mutations, Binding Affinity, and Antibody Escape.
Yang L; Li J; Guo S; Hou C; Liao C; Shi L; Ma X; Jiang S; Zheng B; Fang Y; Ye L; He X
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829998
[TBL] [Abstract][Full Text] [Related]
13. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.
Kang YF; Sun C; Zhuang Z; Yuan RY; Zheng Q; Li JP; Zhou PP; Chen XC; Liu Z; Zhang X; Yu XH; Kong XW; Zhu QY; Zhong Q; Xu M; Zhong NS; Zeng YX; Feng GK; Ke C; Zhao JC; Zeng MS
ACS Nano; 2021 Feb; 15(2):2738-2752. PubMed ID: 33464829
[TBL] [Abstract][Full Text] [Related]
14. Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies.
Zhu X; Mannar D; Srivastava SS; Berezuk AM; Demers JP; Saville JW; Leopold K; Li W; Dimitrov DS; Tuttle KS; Zhou S; Chittori S; Subramaniam S
PLoS Biol; 2021 Apr; 19(4):e3001237. PubMed ID: 33914735
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
Kuba K; Yamaguchi T; Penninger JM
Front Immunol; 2021; 12():732690. PubMed ID: 35003058
[TBL] [Abstract][Full Text] [Related]
16. Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines.
Li J; Wang P; Tracey KJ; Wang H
Mol Med; 2021 May; 27(1):49. PubMed ID: 34022793
[TBL] [Abstract][Full Text] [Related]
17. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
[TBL] [Abstract][Full Text] [Related]
18. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
19. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
Choudhury A; Mukherjee S
J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
[TBL] [Abstract][Full Text] [Related]
20. The basis of a more contagious 501Y.V1 variant of SARS-CoV-2.
Liu H; Zhang Q; Wei P; Chen Z; Aviszus K; Yang J; Downing W; Jiang C; Liang B; Reynoso L; Downey GP; Frankel SK; Kappler J; Marrack P; Zhang G
Cell Res; 2021 Jun; 31(6):720-722. PubMed ID: 33893398
[No Abstract] [Full Text] [Related]
[Next] [New Search]
